Complementary and Alternative Medicine

01Purpose and scope

• This manual supports the course Complementary and Alternative Medicine and serves as a working reference for clinicians, students, pharmacists, and program staff who meet these practices in hospitals, clinics, schools, and community wellness settings.
• The field covers a wide range of approaches. Common examples include acupuncture, herbal and botanical products, dietary supplements, chiropractic manipulation, massage, mind-body methods such as meditation and yoga, and traditional systems such as Ayurveda and traditional Chinese medicine. Some are used alongside conventional treatment, which is often called integrative care, and others are used in place of it. The second use carries the greatest risk because it can delay a diagnosis or a treatment that works.
• How the work looks changes with the setting. In a hospital integrative oncology program, a nurse may check whether a patient is taking a supplement that could interfere with chemotherapy. In a community wellness center, the staff may focus more on scope of practice, consent, and honest description of what the service can and cannot do. In a retail pharmacy, the main task is often product screening and a conversation about interactions.
• This guidance does not replace qualified professional judgment, approved procedures, or required authorization. Licensing rules for acupuncturists, chiropractors, naturopathic doctors, and other practitioners differ by country, state, and province. Requirements for supplements, herbal products, and advertising also vary. Check the current rules with the licensing board, regulator, or institution that governs your work.

02Core principles

• Patient safety comes first. Every practice, product, or technique has a risk profile, even when it is gentle or widely sold. The word natural does not mean free of risk. Some botanicals have strong pharmacological effects, and some products contain undeclared drugs or heavy metals, particularly when they are imported or sold online without quality controls.
• Ask about everything, not only what the patient thinks matters. Patients often do not list supplements, teas, topical creams, or practitioner-recommended products unless asked directly and specifically. Use a question such as which pills, powders, drops, or teas have you taken in the last month, including those bought without a prescription.
• Match the strength of the evidence to the strength of the claim. Evidence for these practices ranges from well-controlled randomized trials to case reports and tradition. A reasonable reviewer asks whether a claim comes from a systematic review, a trial with a comparison group, a small pilot, or a testimonial. Be honest with patients about where the evidence is thin, without dismissing their experience.
• Respect autonomy and informed consent. Adults have the right to make decisions about their own care, including decisions that clinicians disagree with. The clinician's job is to make sure the decision is informed, that risks are named, and that safer options are available if the patient wants them.
• Integration does not mean substitution. A complementary therapy can support comfort, function, or quality of life alongside standard care. It should not postpone the workup of new symptoms, such as unexplained weight loss, bleeding, chest pain, or a changing mole.

03Planning and preparation

• Start by defining the purpose of the encounter. A clinician may be asked to assess a specific practice, to review a product list, to advise on a referral, or to design a program that offers a complementary service. Each purpose calls for different information and different documentation. Write the purpose at the top of the note or project plan so later reviewers understand the reason for the work.
• Identify stakeholders before taking action. Typical stakeholders include the patient or client, the primary clinician, the prescriber of any conventional drugs, the pharmacist, the complementary practitioner if one is involved, the institution's governance or ethics committee, and in research settings the institutional review board. Each has a different question. The patient wants relief and safety. The prescriber wants to know about drug interactions. The institution wants to know its liability and reputation are protected.
• Prepare the tools you need. A basic intake form should ask about current prescriptions, over-the-counter medicines, supplements, herbal products, topical products, recent procedures, pregnancy status where relevant, and any practitioners consulted. Pharmacists and clinicians commonly use reputable drug and supplement interaction references maintained by professional groups or pharmacy publishers. Check the version date of any reference you use, because interaction data changes.
• Gather product information. For supplements and herbal products, record the brand, the exact name on the label, the ingredient list, the dose, the frequency, and the lot number if the patient still has the container. Ask whether the product has been tested by an independent quality program. Labels are not always accurate, so treat a label as a starting point rather than proof of content.
• Decide early whether the case is outside your scope. If the patient needs a diagnostic test, a prescription, or a specialist, the plan should include a clear handoff. If the service requested is one your organization does not offer or is not licensed to provide, say so and identify where the patient can get appropriate help.

04Recommended workflow

1. 1
   : Clarify the patient's goal and the condition being addressed. Ask what they hope the complementary approach will change, such as sleep, joint pain, nausea from treatment, or anxiety. Record the goal in the patient's own words, since it will be the reference point for measuring whether the approach is helping.
2. 2
   : Take a full medication and product history. Use the intake form, then ask follow-up questions in plain language. Confirm the timing of each product relative to conventional doses, since timing can matter for absorption and interaction. Note any product the patient has stopped recently, because withdrawal effects or rebound symptoms can be mistaken for a new problem.
3. 3
   : Screen for safety concerns. Look for interactions with current medicines, known contraindications such as pregnancy or surgery scheduled within days, underlying conditions such as liver or kidney disease, and high-risk groups including children and older adults. Flag any product with potential for serious interaction for review by a pharmacist or prescriber before the patient continues it.
4. 4
   : Review the evidence and the practitioner. If a practitioner is involved, confirm their credentials with the relevant licensing body and ask about their training, insurance, and whether they coordinate with the patient's primary clinician. Review the evidence for the specific technique or product using the strongest sources available, and summarize it in plain language for the patient.
5. 5
   : Discuss options and obtain informed consent. Explain the expected benefit, the known risks, the cost, the time commitment, and the alternatives, including standard care. Document that the patient understood and what they decided. For anything that involves a procedure, such as acupuncture needling or spinal manipulation, follow the consent process your institution or the practitioner's regulator requires.
6. 6
   : Agree on a monitoring plan. Set a review date and define the measures you will watch, such as symptom scores, sleep diary entries, function, or adverse effects. Tell the patient which symptoms should prompt them to stop the product or contact a clinician immediately. Give written contact information for after-hours concerns.
7. 7
   : Follow up and reconcile. At each follow-up, repeat the product history, because products change often. Check whether the patient has started or stopped anything, whether symptoms have changed, and whether adverse effects have appeared. Update the medication list, communicate changes to the primary team, and decide whether to continue, adjust, or stop the approach.

05Quality checks, risk controls and compliance

• Quality control for supplements and herbal products is uneven. In the United States, dietary supplements are regulated under a framework that differs from the one used for prescription drugs, and manufacturers are not required to prove efficacy before marketing. Other countries use different rules. Verify current requirements with the national or regional regulator, and avoid making statements about legal status unless you have checked the current authoritative source.
• Use independent testing marks as one signal, not a guarantee. Third-party testing programs can confirm identity, potency, and the absence of certain contaminants for the batch tested. They do not confirm that a product is right for a given patient. Record the testing body if the patient provides the information, and be cautious with products that make broad therapeutic claims.
• Check claims carefully. Marketing that promises to cure, prevent, or treat a serious disease is a red flag. Clinicians should not repeat such claims in notes or patient handouts. If a patient brings material with strong claims, document that you reviewed it and explain why you do not endorse those claims.
• Report adverse events through the established channels. Most countries have a national system for reporting adverse events and product problems, and many hospitals have an internal incident reporting process. Report suspected serious reactions, contamination concerns, and unexpected interactions. Keep the product lot number and packaging if possible, because they are essential for investigation.
• Protect against specific high-risk combinations. Some well-documented interactions are important to check. St. John's wort, for example, can reduce the effect of several medicines, including certain anticoagulants, some antidepressants, and oral contraceptives. Products containing ginkgo, garlic, fish oil, or high-dose vitamin E can add to bleeding risk when combined with anticoagulants or antiplatelet drugs. Confirm each interaction against a current reference rather than relying on memory alone.
• Respect professional boundaries and privacy. Keep records of the practices discussed, the outcome, and the consent discussion in the patient's record. Share information with other clinicians only within the rules governing patient privacy in your jurisdiction. Do not let a complementary practitioner make changes to prescribed medicines without communication with the prescriber.

06Collaboration and documentation

• Write notes that a colleague can act on without asking you questions. Record the product name, the ingredients if known, the dose, the frequency, the start date, the reason the patient is using it, and any change or stop. Avoid vague entries such as herbs, which leave the next clinician unable to check interactions.
• Share the medication list with the primary team and with the pharmacist. Many interaction problems happen because one clinician did not know that a patient was taking a product started by someone else. A shared list, updated at each visit, is one of the most effective controls available in this field.
• Document the patient's decisions and their reasons. If the patient declines a recommended drug or chooses a complementary approach against advice, record that the risks were explained, that the patient understood them, and what follow-up was agreed. This protects both the patient and the clinician and supports continuity of care.
• Coordinate with complementary practitioners through a clear agreement. Decide who owns which decisions, how often you will communicate, and how urgent concerns will be raised. In an integrated program, a written protocol that names the escalation path is more useful than informal goodwill.
• Use plain language with patients. Patients often assume that a product sold in a store has been tested for their condition. Explain what is known, what is not known, and what to watch for. Provide written information that matches what you said in the consultation.

07Measures and continuous improvement

• Choose a small set of measures tied to the purpose of the program. Useful indicators include completion rate of the product history at intake, percentage of patients with a documented interaction review, number of adverse events reported and their severity, percentage of follow-up visits that update the medication list, and patient-reported outcomes such as pain, sleep, nausea, or function on a standard scale chosen in advance.
• Be careful with self-reported outcomes. Patients who feel helped may not report that they stopped a prescribed drug. Patients who had a poor outcome may stop attending. Ask about adherence and attendance directly, and treat dropout as information rather than as a failure to be hidden.
• Review cases regularly. A short case review each month or quarter, looking at one near miss and one successful integration, helps staff learn without blame. Record what was changed as a result, such as a new intake question or a revised handoff step.
• Compare practice with current guidance. Professional bodies and national health research agencies publish updated guidance on specific therapies. Assign someone to check these sources on a schedule set by your organization, and document when the protocol was last reviewed and by whom.
• Accept the limits of the measures. Small programs cannot detect rare harms, and short follow-up windows miss slow effects. Where the number of patients is small, avoid drawing firm conclusions from a few results, and report uncertainty plainly.

08Common mistakes and how to prevent them

• Asking only about prescriptions. Patients rarely think of teas, creams, or supplements as medicines. Prevent this by using a structured question list that names product types directly and by asking the question at every visit, not only at the first one.
• Accepting label claims as proof. A label can be incomplete, outdated, or inaccurate. Prevent this by recording the label, asking about independent testing, and treating unusual effects as possible signals of a product problem rather than as a normal part of treatment.
• Stopping conventional treatment without discussion. Some patients stop prescribed medicines because they believe a complementary product is enough. Prevent this by asking directly whether any prescribed medicine has been stopped or reduced, and by making sure the prescriber knows.
• Relying on testimonials or tradition alone. Personal experience is real, but it cannot show that a product caused an improvement. Prevent this by stating the evidence level when you discuss options and by suggesting a time-limited trial with a defined measure.
• Failing to close the loop after a referral. A referral to an outside practitioner can disappear into a gap between services. Prevent this by setting a follow-up date, asking the patient to bring the product or treatment record, and requesting a brief written update from the practitioner.
• Delaying the workup of new or worsening symptoms. Patients may attribute a new symptom to a treatment they are already using, or may hope that a complementary approach will resolve it. Prevent this by setting explicit red-flag symptoms in the plan and by requiring prompt medical review when they appear.
• Documenting too little. Vague notes make later review impossible. Prevent this with a template that requires product name, dose, timing, reason for use, and decision made.

09Practical checklist

• Confirm the purpose of the encounter and write it at the top of the note or plan.
• Take a full history of prescriptions, over-the-counter medicines, supplements, herbal and topical products, and practitioner-recommended items.
• Record the product name, ingredients, dose, frequency, start date, and lot number where available.
• Screen for known interactions and contraindications, and flag high-risk combinations for pharmacist or prescriber review.
• Verify the credentials of any complementary practitioner with the relevant licensing body.
• Explain expected benefits, known risks, costs, time commitment, and standard alternatives in plain language.
• Obtain and document informed consent and the patient's decision, following institutional procedure.
• Agree on a monitoring plan with defined measures, a review date, and red-flag symptoms that require immediate contact.
• Share the updated medication list with the primary team and the pharmacist.
• Report suspected adverse events and product problems through the established national or institutional channel.
• Check claims in marketing material before repeating them in notes or handouts.
• Confirm the current regulatory requirements for the product or service with the authoritative source for your jurisdiction.
• Review follow-up data on a set schedule and record the changes made as a result.

★Learning sources

• Micro Degree: Complementary and Alternative Medicine
• Micro Degree: Healthcare Administration Practice
• Micro Degree: Physiotherapy Assistant Operations
• Micro Degree: Cardiac Care Support